Alzheimer's Disease News and Research

RSS

Alzheimer's disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks of daily living. In most people with AD, symptoms first appear after age 60. AD is the most common cause of dementia among older people, but it is not a normal part of aging. Dementia refers to a decline in cognitive function that interferes with daily life and activities. AD starts in a region of the brain that affects recent memory, then gradually spreads to other parts of the brain. Although treatment can slow the progression of AD and help manage its symptoms in some people, currently there is no cure for this devastating disease.

Pico-Tesla commences placebo-controlled Magneceutical Therapy study for Alzheimer's disease

Pico-Tesla, The Magneceutical Company, announced that it has commenced a randomized, double-blind, placebo-controlled pilot study of 30 patients who have Alzheimer's disease symptoms.

6 Jan 2011

Neuroscientist says spatial strategies can reduce risk of dementia

Véronique Bohbot, PhD., neuroscientist at the Douglas Mental Health University Institute and associate professor at McGill University, leads studies on navigational strategies. She presented her findings at the recent meeting of the Society for Neuroscience in San Diego, which could bring light into how we can make better use of our hippocampus in order to reduce the risk of dementia.

5 Jan 2011

Alzheimer's Association applauds President Obama for signing National Alzheimer's Project Act into law

As the leading care, research and advocacy organization for Alzheimer's disease, the Alzheimer's Association® applauds President Obama for signing the National Alzheimer's Project Act(NAPA) into law. NAPA creates for the first time a coordinated national strategy to confront one of America's most feared and costly diseases, a disease that will only plague more baby boomers as they age.

5 Jan 2011

Pico-Tesla announces expansion of Magneceutical Phase III trail for Parkinson's disease

Pico-Tesla, The Magneceutical Company, announced that it has expanded its ongoing Phase III pivotal clinical trial by adding three Principal Investigators, including two university-affiliated clinicians: one in Denver; and one in Tampa.

5 Jan 2011

Take control of your healthcare

Medical decisions are too important to leave in the hands of doctors. That is why Dr. Steven Z. Kussin recently launched a campaign, www.MedicalAdvocate.com, to teach Americans how to take control of their healthcare by becoming their own patient advocate.

4 Jan 2011

Baby boomers lack knowledge about Alzheimer's disease

An online survey of baby boomers across Canada conducted by the Alzheimer Society reveals a worrying lack of awareness about Alzheimer's disease.

4 Jan 2011

New approach to Alzheimer’s care

Protocols and practices at an Arizona nursing home that allows patients with Alzheimer’s disease freedom to eat and sleep when they want makes appears to make them happier and easier to care for, the New York Times reports. Beatitudes, a ministry of the Church of the Beatitude, has also done away with restraints. Each patient is cared for according to his/her individual needs.

3 Jan 2011

BIOMICs oversees SGIker DNA Bank to know genetic heritage of Basque lineage

The BIOMICs Group, based at the Lucio Lascaray building in the álava/Araba campus of the University of the Basque Country, is specially known for overseeing the SGIker DNA Bank, not only undertaking this task, but also feeding data into the gene research bank and making good use of it for their own lines of research.

28 Dec 2010

Intellect obtains pharmacokinetic data from OX1 Phase 1b trial for Alzheimer's disease

Intellect Neurosciences, Inc., a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and multiple licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced that it has obtained a draft pharmacokinetic report from its completed Phase 1b trial for its lead Alzheimer's candidate, OX1. The Company previously reported on the safety aspects of the trial, which demonstrated that OX1 is safe and well tolerated at all dose levels tested.

28 Dec 2010

Epilepsy not getting the public attention and research funding it deserves

Epilepsy, a common and serious neurologic disorder that affects millions of people, is not getting the public attention and funding for research it deserves, according to an editorial on a study published in the January 4, 2011, print issue of Neurology®, the medical journal of the American Academy of Neurology.

28 Dec 2010

Transition, Elan to modify collaboration agreement for development, commercialization of ELND005

Transition Therapeutics Inc. today announced that the Company and Elan Corporation, plc have mutually agreed to modify their collaboration agreement for the development and commercialization of ELND005.

27 Dec 2010

Great River Medical Center's Board of Directors approve construction of new long-term-care center

Great River Medical Center's Board of Directors has approved construction of a new long-term-care center on the hospital's West Burlington, Iowa campus. It will replace the existing Klein Center at 2910 Madison Ave., Burlington, Iowa.

27 Dec 2010

AMPK activates autophagy by activating ATG1 enzyme

Researchers at the Salk Institute for Biological Studies have discovered how AMPK, a metabolic master switch that springs into gear when cells run low on energy, revs up a cellular recycling program to free up essential molecular building blocks in times of need.

24 Dec 2010

Pfizer's sublicensing of Tanaproget triggers $1 million upfront payment to Ligand

Ligand Pharmaceuticals Incorporated announced today that its partner Pfizer, Inc. has granted a sublicense to a multi-national pharmaceutical company for Tanaproget, also known as NSP-989. As a result, Ligand will receive an upfront payment of $1 million from Pfizer. Ligand is entitled to clinical and regulatory milestone payments from Pfizer as Tanaproget advances through the development process, as well as tiered royalties on net sales.

23 Dec 2010

Scientist discovers molecular switch controlling synthesis of ribosomes

A scientist from the Florida campus of The Scripps Research Institute has discovered a molecular switch that controls the synthesis of ribosomes. Ribosomes are the large machineries inside all living cells that produce proteins, the basic working units of any cell. These new findings offer a novel target for potential treatments for a range of diseases, including cancer.

23 Dec 2010

Fried fish consumption may increase risk of stroke

People living in the "stroke belt" states eat more fried fish than people living in the rest of the country, which may contribute to the high rate of death from stroke in those states, according to a study published in the December 22, 2010, online issue of Neurology®, the medical journal of the American Academy of Neurology.

23 Dec 2010

Time magazine declares NYSCF member as 2010 "Person who Matters" for innovative stem cell research

The New York Stem Cell Foundation extends congratulations to Derrick Rossi, PhD, a member of the inaugural class of NYSCF-Robertson Investigators, who was named one of Time Magazine's 2010 "People Who Mattered" in the December 27, 2010 Person of the Year Issue.

22 Dec 2010

Charity Navigator provides four-star rating to Alzheimer's Foundation of America

The Alzheimer's Foundation of America (AFA) announced today that it has received the highest rating -- four stars -- from Charity Navigator, the nation's largest independent evaluator of charitable organizations.

22 Dec 2010

Anavex files regulatory submission in Germany for ANAVEX 2-73 Phase I trial in Alzheimer's disease

Anavex Life Sciences Corp. announced today that it has filed the regulatory submission for ANAVEX 2-73 with the German Health Authority, BfArM, and the local Ethics Committee of Saxony to begin clinical studies for ANAVEX 2-73, its lead compound for the treatment of Alzheimer's disease.

21 Dec 2010

ExonHit awarded QTDP grants for AclarusDx and EHT 107 programs

ExonHit Therapeutics today announced that the Company was awarded two grants to support two of its Research & Development projects under the Qualifying Therapeutic Discovery Project Program: AclarusDx™ in Alzheimer's disease and the EHT 107 program in oncology.

21 Dec 2010

Alzheimer's Disease News and Research

Further Reading

Pico-Tesla commences placebo-controlled Magneceutical Therapy study for Alzheimer's disease

Neuroscientist says spatial strategies can reduce risk of dementia

Alzheimer's Association applauds President Obama for signing National Alzheimer's Project Act into law

Pico-Tesla announces expansion of Magneceutical Phase III trail for Parkinson's disease

Take control of your healthcare

Baby boomers lack knowledge about Alzheimer's disease

New approach to Alzheimer’s care

BIOMICs oversees SGIker DNA Bank to know genetic heritage of Basque lineage

Intellect obtains pharmacokinetic data from OX1 Phase 1b trial for Alzheimer's disease

Epilepsy not getting the public attention and research funding it deserves

Transition, Elan to modify collaboration agreement for development, commercialization of ELND005

Great River Medical Center's Board of Directors approve construction of new long-term-care center

AMPK activates autophagy by activating ATG1 enzyme

Pfizer's sublicensing of Tanaproget triggers $1 million upfront payment to Ligand

Scientist discovers molecular switch controlling synthesis of ribosomes

Fried fish consumption may increase risk of stroke

Time magazine declares NYSCF member as 2010 "Person who Matters" for innovative stem cell research

Charity Navigator provides four-star rating to Alzheimer's Foundation of America

Anavex files regulatory submission in Germany for ANAVEX 2-73 Phase I trial in Alzheimer's disease

ExonHit awarded QTDP grants for AclarusDx and EHT 107 programs

Human iPSCs: A Full Guide to Advanced in Vitro Models and Applications eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News